Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling

Liver International

Volumn 33, Issue 4, 2013, Pages 561-568

  Reiberger, Thomas ^a   Payer, Berit Anna ^a   Schwabl, Philipp ^a   Hayden, Hubert ^a   Horvatits, Thomas ^a   Jäger, Bernhard ^a   Hummel, Thomas ^a   Mitterhauser, Markus ^a   Trauner, Michael ^a   Fuhrmann, Valentin ^a   Angermayr, Bernhard ^a   Peck Radosavljevic, Markus ^a   Vienna Hepatic Hemodynamic Lab, ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Animal study; Nebivolol; Portal hypertension

Indexed keywords

GLUTATHIONE; GLUTATHIONE DISULFIDE; MICROSPHERE; NEBIVOLOL; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE DUCT LIGATION; BLOOD FLOW; COLLATERAL CIRCULATION; CONTROLLED STUDY; DRUG MEGADOSE; HEART RATE; LIVER CIRRHOSIS; LOW DRUG DOSE; MALE; MEAN ARTERIAL PRESSURE; MODULATION; NONHUMAN; OXIDATION REDUCTION REACTION; PORTAL VEIN BLOOD PRESSURE; PORTOSYSTEMIC COLLATERAL BLOOD FLOW; QUANTITATIVE ANALYSIS; RAT; SHAM PROCEDURE; SIGNAL TRANSDUCTION; SPLANCHNIC BLOOD FLOW; SUPERIOR MESENTERIC ARTERY BLOOD FLOW;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BENZOPYRANS; BLOOD FLOW VELOCITY; COLLATERAL CIRCULATION; COMMON BILE DUCT; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOLAMINES; GLUTATHIONE; HEART RATE; HYPERTENSION, PORTAL; LIGATION; LIVER; LIVER CIRCULATION; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MESENTERIC ARTERY, SUPERIOR; NITRIC OXIDE; OXIDATION-REDUCTION; PORTAL PRESSURE; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SPLANCHNIC CIRCULATION; UP-REGULATION;

EID: 84875024023     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12101     Document Type: Article

References (25)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29(Suppl 1): 74-81.
2. Fleming KM, Aithal GP, Solaymani-Dodaran M, Card TR, West J. Incidence and prevalence of cirrhosis in the United Kingdom, 1992-2001: a general population-based study. J Hepatol 2008; 49: 732-8.
3. Ferlitsch M, Reiberger T, Hoke M, et al. Von willebrand factor as new non-invasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology 2012; 56: 1439-47.
4. Bosch J, Garcia-Pagan JC. Complications of cirrhosis. I. Portal hypertension. J. Hepatol. 2000; 32(Suppl 1): 141-56.
5. Peck-Radosavljevic M, Trauner M, Schreiber F. Austrian consensus on the definition and treatment of portal hypertension and its complications. Endoscopy 2005; 37: 667-73.
6. Reiberger T, Ferlitsch A, Payer BA, et al. Non-selective beta-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis. J Gastroenterol 2012; 47: 561-8.
7. De Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010; 53: 762-8.
8. Angermayr B, Cejna M, Karnel F, et al. Transjugular intrahepatic portosystemic shunt in Vienna-a decade later. Wien Klin Wochenschr 2004; 116(17-18): 608-13.
9. Merkel C, Bolognesi M, Sacerdoti D, et al. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000; 32: 930-4.
10. Reiberger T, Ferlitsch A, Payer BA, et al. Noninvasive screening for liver fibrosis and portal hypertension by transient elastography-a large single center experience. Wien Klin Wochenschr 2012; 124: 395-402.
11. Bosch J, Berzigotti A, Garcia-Pagan JC, Abraldes JG. The management of portal hypertension: rational basis, available treatments and future options. J Hepatol 2008; 48(Suppl 1): S68-92.
12. Maffei A, Lembo G. Nitric oxide mechanisms of nebivolol. Ther Adv Cardiovasc Dis 2009; 3: 317-27.
13. Agabiti Rosei E, Rizzoni D. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs 2007; 67(8): 1097-107.
14. Nuttall SL, Routledge HC, Kendall MJ. A comparison of the beta1-selectivity of three beta1-selective beta-blockers. J Clin Pharm Ther 2003; 28: 179-86.
15. Bundkirchen A, Brixius K, Bolck B, Nguyen Q, Schwinger RH. Beta 1-adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I]iodocyanopindolol binding studies. Eur J Pharmacol 2003; 460: 19-26.
16. (R) (nebivolol). http://wwwfrxcom/pi/Bystolic_pipdf 2011; (revised December 2011).
17. Weiss RJ, Saunders E, Greathouse M. Efficacy and tolerability of nebivolol in stage I-II hypertension: a pooled analysis of data from three randomized, placebo-controlled monotherapy trials. Clin Ther 2011; 33: 1150-61.
18. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215-25.
19. Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995; 274: 1067-71.
20. De Groot AA, Mathy MJ, Van Zwieten PA, Peters SL. Antioxidant activity of nebivolol in the rat aorta. J Cardiovasc Pharmacol 2004; 43: 148-53.
21. Fratta Pasini A, Garbin U, Nava MC, et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 2005; 23: 589-96.
22. Ignarro LJ, Sisodia M, Trinh K, et al. Nebivolol inhibits vascular smooth muscle cell proliferation by mechanisms involving nitric oxide but not cyclic GMP. Nitric Oxide 2002; 7(2): 83-90.
23. Fedulenkova LV. Correction of portal hypertension and renal dysfunction with help of nebivolol and lizinopril in patients with hepatic cirrhosis. Eksp Klin Gastroenterol 2009; 5: 130-7.
24. Fickert P, Zollner G, Fuchsbichler A, et al. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002; 123: 1238-51.
25. Reiberger T, Angermayr B, Schwabl P, et al. Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. J Hepatol 2009; 51: 865-73.